{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:26Z","timestamp":1791357386310,"version":"4.3.1"},"reference-count":60,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or as adjunctive therapy with lithium or valproate. The use of low doses of atypical antipsychotics is an essential component of early intervention in psychosis, but little has yet been studied on first episode cannabis-induced psychosis. For its particular performance and tolerability, lurasidone is becoming an important option for the treatment of first-episode psychosis in youth. Case presentation four patients experiencing first cannabis-induced psychotic episode were treated with lurasidone. In all patients, there was an improvement in the clinical picture of psychosis. The recovery was positive, not only with the remission of positive and negative symptoms, but also regarding disruptive behaviour, with the return of functioning. All the patients were treated with lurasidone, with a target dose of 74\u2013128 mg\/day. No significant side effects were reported. Conclusion: There are non-controlled studies for the use of lurasidone in first episode psychosis cannabis induced. These findings suggest that lurasidone is an atypical antipsychotic beneficial in this clinical picture. Treatment with medium-high doses of lurasidone could be effective and tolerable in this phase of the disorder. Randomized control trials with longer follow-up are recommended to confirm these positive results.<\/jats:p>","DOI":"10.3390\/ijerph192316057","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T01:54:31Z","timestamp":1669859671000},"page":"16057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-2530","authenticated-orcid":false,"given":"Valerio","family":"Ricci","sequence":"first","affiliation":[{"name":"San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2341","authenticated-orcid":false,"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Imaging and Clinical Sciences, Universit\u00e0 Degli Studi G. D\u2019Annunzio Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-5058","authenticated-orcid":false,"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"National Health Service, Department of Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital \u201cG. Mazzini\u201d, 64100 Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[{"name":"San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy"},{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10043 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.15288\/jsad.2012.73.820","article-title":"Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample","volume":"73","author":"Moss","year":"2012","journal-title":"J. Stud. Alcohol Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1360-0443.2007.02064.x","article-title":"The natural course of cannabis use, abuse and dependence during the first decades of life","volume":"103","author":"Perkonigg","year":"2008","journal-title":"Addiction"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, Amercican Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.eurpsy.2011.03.001","article-title":"Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis","volume":"27","author":"Schimmelmann","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affectivemental health outcomes: A systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/aje\/kwf043","article-title":"Cannabis use and psychosis: A longitudinal population-based study","volume":"156","author":"Back","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder across Europe (EU-GEI): A Multicentre Case-Control Study","volume":"6","author":"Quattrone","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study","volume":"2","author":"Marconi","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/schbul\/sbv154","article-title":"Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study","volume":"42","author":"Seddon","year":"2016","journal-title":"Schizophr. Bull."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1017\/S0033291716001999","article-title":"Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder","volume":"46","author":"Ringen","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/schbul\/sbi027","article-title":"The environment and schizophrenia: The role of cannabis use","volume":"31","author":"Henquet","year":"2005","journal-title":"Schizophr. Bull."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(07)61653-5","article-title":"Cannabis and psychosis","volume":"370","year":"2007","journal-title":"Lancet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-Analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","article-title":"Cannabis and mental illness: A review","volume":"269","author":"Lowe","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.2174\/138161212802884816","article-title":"The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: Meta-analysis of possible confounding factors","volume":"18","author":"Myles","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/schbul\/sbq153","article-title":"The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia","volume":"38","author":"Leeson","year":"2012","journal-title":"Schizophr. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2009.04.005","article-title":"Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study)","volume":"113","author":"Baeza","year":"2009","journal-title":"Schizophr. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2007.06.004","article-title":"Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients","volume":"95","author":"Schimmelmann","year":"2007","journal-title":"Schizophr. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamapsychiatry.2018.2552","article-title":"Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis","volume":"76","author":"Rosengard","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1017\/S0033291720000082","article-title":"Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study","volume":"51","author":"Quattrone","year":"2020","journal-title":"Psychol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109118","DOI":"10.1016\/j.drugalcdep.2021.109118","article-title":"Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study","volume":"229","author":"Ricci","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ricci, V. (2021). Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182312632"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2016.04.042","article-title":"Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia","volume":"175","author":"Baudin","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e009888","DOI":"10.1136\/bmjopen-2015-009888","article-title":"Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: An observational study","volume":"6","author":"Patel","year":"2016","journal-title":"BMJ Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2215-0366(17)30233-X","article-title":"Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: A prospective analysis","volume":"4","author":"Schoeler","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00406-019-01068-z","article-title":"Cannabis use and psychosis: A review of reviews","volume":"270","author":"Hasan","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1017\/S0033291714003092","article-title":"Course of cannabis use and clinical outcome in patients with non-affective psychosis: A 3-year follow-up study","volume":"45","author":"Velthorst","year":"2015","journal-title":"Psychol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.psychres.2016.11.007","article-title":"Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program","volume":"247","author":"Salvat","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_30","unstructured":"(2015, March 25). Latuda\u00ae (Lurasidone HCl) Tablets [Package Insert], Available online: http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf."},{"key":"ref_31","unstructured":"European Medicines Agency (2014). Annex I: Summary of Product Charateristics, European Medicines Agency. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/002713\/WC500164683.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/JCP.0000000000000562","article-title":"Comment on An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder","volume":"36","author":"McGrane","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jad.2020.08.048","article-title":"Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model","volume":"277","author":"Goldberg","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/wps.20341","article-title":"Traditional marijuana, high-potency cannabis and synthetic cannabinoids: Increasing risk for psychosis","volume":"15","author":"Murray","year":"2016","journal-title":"World Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0269881105049040","article-title":"Cannabis as a risk factor for psychosis: Systematic review","volume":"19","author":"Semple","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","article-title":"Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis 2018","volume":"175","author":"Starzer","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Corazza, O., and Roman-Urrestarazu, A. (2018). Handbook of Novel Psychoactive Substances, Routledge.","DOI":"10.4324\/9781315158082"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2017.11.001","article-title":"Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review","volume":"197","author":"Wilson","year":"2017","journal-title":"Schizophr. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2125.2012.04474.x","article-title":"Future pharmacological treatments for substance use disorders","volume":"77","author":"Forray","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14656566.2015.983472","article-title":"Pharmacological treatments for drug misuse and dependence","volume":"16","author":"Reed","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNF.0b013e3182908330","article-title":"Aripiprazole for Treating Cannabis-Induced Psychotic Symptoms in Ultrahigh-Risk Individuals","volume":"36","author":"Rolland","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: Presentation of a case report","volume":"40","author":"Ricci","year":"2022","journal-title":"J. Addict. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajad.13241","article-title":"Case Series: Cariprazine for treatment of methamphetamine use disorder","volume":"31","author":"Truong","year":"2022","journal-title":"Am. J. Addict."},{"key":"ref_46","unstructured":"(2015, March 25). Lurasidone Latuda\u2014European Public Assessment Report (EPAR) EMA\/113836\/2014. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/latuda-epar-public-assessment-report_en.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6 weeks, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psych. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80mg\/day and 160 mg\/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: A 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal studu of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_55","first-page":"1","article-title":"Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-na\u00efve versus previously treated adolescents with an acute exacerbation of schizophrenia","volume":"65","author":"Correl","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0000000000001506","article-title":"Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis","volume":"42","author":"Yee","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaac.2021.03.021","article-title":"Systematic Review and Network Meta-analysis: Efficacy and Safety of Second- Generation Antipsychotics in Youths With Bipolar Depression","volume":"61","author":"DelBello","year":"2022","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1192\/j.eurpsy.2021.30","article-title":"Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies","volume":"64","author":"Costamagna","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.genhosppsych.2017.05.002","article-title":"Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia","volume":"47","author":"Allen","year":"2017","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: Analysis of 4 pooled, 6-week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectr."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/23\/16057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:47Z","timestamp":1760146247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/23\/16057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":60,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijerph192316057"],"URL":"https:\/\/doi.org\/10.3390\/ijerph192316057","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}